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012.06.0Abstract Introduction: Cardiovascular magnetic resonance (CMR) with delayed contrast
enhancement (DCE) has been recently emerged as an easy-to-perform method for differentiation
between normal and diseased myocardium. The aim of this study was to delineate the etiology of
chronic heart failure (CHF) non-invasively using DCE-CMR at 3.0 Tesla.
Methods: Thirty-four patients with CHF, left ventricular ejection fraction (LVEF) <40%, and no
clear history or objective evidence of coronary artery disease (CAD) were evaluated by contrast-
enhanced CMR (Philips Achiva 3.0 T) and conventional coronary angiography. Signiﬁcant CAD
was deﬁned as >50% diameter stenosis of major epicardial coronary vessel.
Results: Fifteen patients showed subendocardial and/or transmural pattern of DCE (group A).
Nineteen patients showed pattern of mid wall and/or subepicardial or no DCE (group B). Group
A patients were older (52 ± 9 vs. 45 ± 10 years, p= 0.042), had higher prevalence of diabetes
mellitus, hypertension and dyslipidemia, p= 0.001. LVEF was comparable in both groups. Coro-
nary angiography showed signiﬁcant CAD in 14/15 patients in group A. The other patient had cor-
onary artery ectasia of the left anterior descending coronary artery. Normal angiogram was seen in
18/19 patients in group B. The other patient had 60% diameter stenosis of mid dominant right cor-
onary artery. The sensitivity and speciﬁcity of DCE-CMR for detection of CAD were 93.3% and
94.7% respectively. The positive likelihood ratio was 17.74.El Nadi Street, Haram, Giza
, mobile: +20 2 010 1900014;
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An important assessment in patients with chronic heart failure
(CHF) is whether left ventricular dysfunction is due to coro-
nary artery disease (CAD) or due to non-coronary etiology.
This differentiation is clinically important as ischemic cardio-
myopathy (ICM) patients are associated with shorter mean
survival than patients with idiopathic dilated cardiomyopathy
(DCM).1 In addition, the management plan is altered as pa-
tients with ICM may beneﬁt from revascularization and sec-
ondary preventive pharmacotherapy, whereas patients with
DCM may have better response to usual anti-failure measures
including beta blockade.2 Determining the exact etiology is
sometimes difﬁcult using the currently available imaging tech-
niques such as echocardiography, radionuclide imaging or cor-
onary angiography, especially if history of CAD is lacking.
Over the last decade, cardiac magnetic resonance (CMR)
imaging has become a well established non-invasive modality
for visualizing myocardial diseases.3 The delayed contrast
enhancement (DCE) technique using gadolinium based con-
trast media is a newly developed technique that allows direct
visualization of myocardial necrosis or ﬁbrosis as regions of
bright signal (hyperenhancement) compared with normal myo-
cardium.4–6 The pattern of hyperenhancement may favor one
diagnosis over the other. Recently, CMR at 3.0 Tesla has be-
come available in the Egyptian market, and it has demon-
strated advantages over 1.5 Tesla for a broad range of
cardiac clinical applications especially perfusion imaging, de-
layed enhancement and myocardial tagging.7
The aim of this study was to evaluate the feasibility of
DCE-CMR at 3.0 Tesla to differentiate between ICM and
DCM in patients with CHF and no clear history (or objective
evidence) of CAD.
2. Materials and methods
2.1. Study population
The study included 34 patients with CHF (mean age of
48 ± 10 years, males = 26) and left ventricular ejection frac-
tion (LVEF) <40% by echocardiography. The main com-
plaint of all patients was shortness of breath. No patient
gave clear history suggestive of myocardial infarction or had
electrocardiogram (ECG) showing pathological Q waves or
left bundle branch block. ECGs of all patients showed either
poor R wave progression or non-speciﬁc ST-T changes with
variable degrees of intraventricular conduction defects.
Cardiovascular risk proﬁle including diabetes mellitus,
hypertension, dyslipidemia and smoking was obtained. Hyper-
tension was deﬁned as systolic blood pressure >140 mm Hg
and/or diastolic blood pressure>90 mm Hg and/or use of anti-
hypertensive medications. Diabetes mellitus was deﬁned as fast-
ing plasma glucose level >126 mg/dl and/or use of blood
glucose lowering medications. Dyslipidemia was deﬁned as ser-
um cholesterol >200 mg/dl, and/or HDL <40 mg/dl and/oruse of lipid loweringmedications. Smokers were deﬁned as those
who were currently smoking or had quit within the last 5 years.
Patients with hypertrophic cardiomyopathy, inﬁltrative cardio-
myopathy, valvular or congenital heart disease were excluded.
All patients were subjected to contrast-enhanced CMR, fol-
lowed by conventional coronary angiography within one week.
The protocol of the present study was approved by the local
institutional review board and all patients gave a written in-
formed consent.
2.2. Cardiac magnetic resonance
A Philips Achieva (3.0 Tesla) superconducting magnet (Neth-
erlands) was used for all CMR examinations. The CMR pro-
tocol included a functional study of the left ventricle using
an ECG-triggered, breath-hold balanced turbo ﬁeld echo se-
quence (b-TFE) in short axis view from the mitral annulus
to the apex with the following parameters: repetition time
(TR)/ echo time (TE), 4.4/2.5; ﬂip angle, 15; slice thickness,
8 mm and scan time of 7–12 s.
For DCE imaging, intravenous gadolinium-DTPA was gi-
ven (0.2 mmol/kg) followed 10–15 min later by breath-hold
segmented inversion recovery balanced turbo ﬁeld echo (IR-
b-TFE) in the same short axis location as the cine images with
the following parameters: TR/TE, 3.8/1.86; ﬂip angle, 15; slice
thickness, 8 mm and scan time of 9–15 s. Additional planes for
imaging were used in some patients including horizontal and
vertical long axis views.
2.3. Image analysis
Analysis of CMR (DICOM) images were performed using
Brilliance 170 P workstation. All images were interpreted by
two experienced radiologists who were blinded to patient’s
clinical data.
Determination of the presence or absence of delayed
gadolinium enhancement was done by reviewing all con-
trast-enhanced images. Enhancement patterns were classiﬁed
into subendocardial, transmural (more than 50% of wall
thickness), subepicardial or mid wall (Fig. 1). DCE was
judged to be of ischemic origin if it was subendocardial or
transmural (group A). On the other hand, subepicardial,
mid wall or no DCE was judged to be of non-ischemic etiol-
ogy (group B).8–10
The localization of DCE within the left ventricle was de-
scribed using the American Heart Association segmentation
of the left ventricle.11
2.4. Coronary angiography
Coronary angiography was performed by an experienced car-
diologist according to standard procedures using the transfe-
moral Judkins technique in all patients. At least, six different
projections were performed to visualize the left coronary sys-
tem and two projections to visualize the right coronary artery.
Figure 1 Patterns of DCE-CMR. (a) Short-axis CMR image showing transmural DCE. (b) Short-axis CMR image showing
subendocardial DCE. (c) Short-axis CMR image showing subepicardial DCE. (d) Four-chamber CMR image showing midwall DCE. (e)
Four-chamber CMR image showing no DCE.
Role of delayed contrast enhancement cardiovascular magnetic resonance at 3.0 Tesla in patients with chronic heart failure 199Quantitative coronary analysis (QCA, Philips, Eindhoven,
Netherlands) was used to assess lesion severity. Signiﬁcant
CAD was deﬁned as >50% diameter stenosis of one or more
major epicardial coronary vessel.
2.5. Statistical analysis
Continuous variables were described as mean ± SD. Categor-
ical data were presented with absolute frequencies and percent-
ages. Fisher exact test was used to compare categorical data.
Unpaired t tests were used to evaluate differences between
the two patients groups. Values of P < 0.05 were considered
statistically signiﬁcant. Estimations of sensitivity, speciﬁcity
and likelihood ratio were obtained using the usual methods
of inference for proportions.12 All statistical analyses were
done using SPSS version 16.0 software for Windows (SPSS
Inc. Chicago, IL).
3. Results
3.1. Demographic and clinical characteristics
According to the pattern of DCE, there were 15 patients who
belonged to group A (subendocardial, n= 1; transmural,
n= 7, or both, n= 7) and 19 patients who belonged to group
B (subepicardial, n= 1; mid wall, n= 7 or no DCE, n= 11).
LVEF as measured by CMR was comparable in group A and
B (22 ± 6 vs. 23 ± 7 respectively, p= 0.663). Group A pa-tients were older and had a higher prevalence of hypertension,
diabetes and dyslipidemia. Table 1 shows the demographic
characteristics of both groups.
3.2. Delayed contrast enhancement CMR
Analysis of group A patients revealed that according to the 17-
segment model of the left ventricle proposed by the American
Heart Association (AHA), the left anterior descending (LAD)
territory was involved in 11/15 patients, the left circumﬂex
(LCx) territory and the right coronary artery (RCA) territory
were involved in 14/15 patients. Table 2 demonstrates the prev-
alence of myocardial segments that showed DCE in group A.
Apical segments as well as mid anterior and mid anteroseptal
segments were the most prevalent segments that showed DCE
(LAD territory).
3.3. Coronary angiography
Results of coronary angiography showed that 14/15 patients in
group A had signiﬁcant coronary artery disease (eight patients
had multivessel disease, 4 patients had two vessel disease and 2
patients had single vessel disease). The other patient had coro-
nary artery ectasia involving the LAD. LAD and its branches
were involved in 13/15 patients, LCx in 9/15 and RCA in 10/15
patients. Coronary angiography showed that 18/19 patients in
group B had normal angiogram. One patient only had 60%
diameter stenosis of the mid dominant RCA.
Table 1 Demographic characteristics of group A and B.
Demographic and clinical data Group A (n= 15) Group B (n= 19) P value
Age (years) 52 ± 9 45 ± 10 0.042
Male/female 13/2 13/6 0.256
Diabetes mellitus (%) 8 (53) 3 (16) 0.03
Hypertension (%) 9 (60) 2 (11) 0.003
Dyslipidemia (%) 8 (53) 2 (11) 0.009
Smoking (%) 12 (80) 10 (53) 0.190
Table 2 Prevalence of myocardial segments showing DCE in
group A.
Segment Number of patients (%)
Basal anterior 7 (46.7)
Basal anteroseptal 4 (26.7)
Basal inferoseptal 0 (0)
Basal inferior 3 (20)
Basal inferolateral 4 (26.7)
Basal anterolateral 5 (33.3)
Mid anterior 11 (73.3)
Mid anteroseptal 11 (73.3)
Mid inferoseptal 2 (13.3)
Mid inferior 6 (40)
Mid inferolateral 5 (33.3)
Mid anterolateral 6 (40)
Apical anterior 11 (73.3)
Apical septal 11 (73.3)
Apical inferior 13 (86.7)
Apical lateral 12 (80)
Apex 11 (73.3)
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94.7% respectively for detection of CAD as a cause of CHF.
The positive likelihood ratio was 17.74 which indicates that
the odds ratio for CAD was about 17 times greater after a po-
sitive DCE-CMR. Table 3 showed DCE-CMR in the diagnosis
of CAD.
4. Discussion
We investigated the ability of DCE-CMR for differentiation
between ICM and DCM as the underlying cause of CHF in pa-
tients with no clear history or objective evidence of CAD. Our
results showed that 93.3% of patients with signiﬁcant CAD by
coronary angiography, had the pattern of subendocardial and/
or transmural DCE. On the other hand, 94.7% of patients
without signiﬁcant CAD on angiogram were shown to haveTable 3 DCE-CMR in the diagnosis of CAD.
DCE-CMR
Subendocardial and/or transmural DCE
Mid wall and/or subepicardial or no DCE
DCE= delayed contrast enhancement; CMR= cardiovascular magn
angiography.no DCE or the pattern of mid wall and/or subepicardial
enhancement.
Our results matches with what was published previously
that subendocardial and/or transmural DCE have been de-
tected in 94% of patients with ICM with or without previous
history of myocardial infarction. Meanwhile the same pattern
was shown in only 9% of patients with DCM.9,13 Wu et al.14
and McCrohen et al.8 had previously shown that 100% of pa-
tients with ICM had subendocardial and/or transmural DCE,
however, those patients had a documented history of previous
myocardial infarction.
Only one patient in group A had coronary artery ectasia of
the LAD with no signiﬁcant stenotic lesion. He was shown to
have the pattern of transmural enhancement. This could be ex-
plained by the presence of previous silent myocardial infarc-
tion or evidence of necrosis that accompanies left ventricular
systolic dysfunction. In a small follow up study of ﬁve patients
with coronary artery ectasia who suffered a myocardial infarc-
tion, the clinical event was attributed to thrombus formation
in a non-stenosed aneurysmatic arterial segment.15 Another
patient but in group B had 60% stenosis of the mid dominant
RCA. He showed the pattern of mid wall DCE. This could be
explained by the possibility that CAD in this patient may not
be the cause of left ventricular dysfunction. A recent study16
showed that 14% of patients with acute new-onset heart failure
and left ventricular systolic dysfunction of uncertain etiology,
did not present subendocardial or transmural DCE despite
showing obstructive CAD on angiography.
The positive likelihood ratio of DCE-CMR in our study
was 17.74 which means that for every 17 times the DCE is po-
sitive in patients with CAD, it will be positive once in patient
who do not have the disease. This is higher than the results of
Munoz et al.16 who showed a positive likelihood ratio of 13.03
in his study with CMR 1.5 Tesla acquisition system. In fact,
the higher achievable signal-to-noise ratio (SNR) at 3.0 Tesla
may beneﬁt cardiac scar imaging by providing higher contrast
between healthy and diseased (non-viable) myocardium.7 In
patients with a history of myocardial infarction, a higher im-
age of DCE was demonstrated at 3.0 Tesla compared to 1.5
Tesla.17CAD (by CA) No CAD (by CA)
14 (93.3%) 1(6.7%)
1 (5.3%) 18 (94.7%)
etic resonance; CAD= coronary artery disease; CA= coronary
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The extent of DCE-CMR is considered a marker of left ven-
tricular remodeling from both ischemic and non-ischemic dis-
eases.18 The pattern of DCE can establish the etiology of left
ventricular systolic dysfunction in patients with CHF. This
can provide information that alters the management plan over
and above the standard imaging techniques.19 Several recent
studies examined the potential beneﬁts of DCE-CMR at 3.0
Tesla like the possibility of reducing the dose of contrast
agent20 and the better delineation of infarct zones from peri-in-
farct regions which may be a focus of ventricular
arrhythmias.21
5. Conclusion
In patients with CHF, left ventricular dysfunction and no clear
history or objective evidence of CAD, DCE-CMR at 3.0 Tesla
can differentiate between ICM and DCM and can be consid-
ered complementary to echocardiography for delineation of
etiological diagnosis.
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